tetano
Editor, Senior Moderator
Antivir Chem Chemother. 2012 Feb 20. doi: 10.3851/IMP2077. [Epub ahead of print]
Anti-virus activity of recombinant mouse beta-defensin 3 against influenza A virus in vitro and in vivo.
Jiang Y, Yang D, Li W, Wang B, Jiang Z, Li M.
Source
Department of Microbiology, Guiyang Medical College, Guiyang 550004, China.
Abstract
BACKGROUND:
Influenza is one of the oldest and most common infections, causing significant morbidity and mortality. Mammalian beta-defensins are small peptides of about 4.5-6 kDa in mass and are effectors of the innate immune response with potent anti-microbial activity. In this paper, we focused on the anti-influenza A activity of the recombinant mouse β-defensin 3 (rMBD-3) in vivo and in vitro.
METHODS:
The rMBD-3 peptide was added to MDCK cells at different stages of influenza A virus (IAV) A/PR/8/34 (H1N1) infection and its virus inhibitory properties were determined. Mice were infected with IAV and treated with rMBD-3 peptide from 12 hours post infection. The effect of rMBD-3 peptide was determined by measurement of pulmonary viral load, pathology, consolidation and mortality. In addition, the expression of IL-12, IFN-γ and TNF-α genes in mice with or without rMBD-3 treatment was determined by semi-quantitative RT-PCR.
RESULTS:
rMBD-3 was shown to protect MDCK cells against IAV infection and have a major role in inhibition of adsorption and uptake by cells of IAV. Following addition of 100 μg/ml rMBD-3 to MDCK cell medium approximately 80% of cells were protected from infection in vitro. rMBD-3 given by tail vein injection (10 mg/kg/day) was the most effective method to improve the survival rate of the mice. Treatment with rMBD-3 was found to up-regulate IFN-γ and IL-12 gene expression, but reduced expression of the TNF-α gene.
CONCLUSIONS:
These results demonstrate that rMBD-3 possesses anti-influenza virus activity both in vivo and in vitro that might be of therapeutic use. KEYWORDS: rMBD-3; influenza A virus; anti-virus activity; in vitro and in vivo.
PMID:
22345365
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22345365
Anti-virus activity of recombinant mouse beta-defensin 3 against influenza A virus in vitro and in vivo.
Jiang Y, Yang D, Li W, Wang B, Jiang Z, Li M.
Source
Department of Microbiology, Guiyang Medical College, Guiyang 550004, China.
Abstract
BACKGROUND:
Influenza is one of the oldest and most common infections, causing significant morbidity and mortality. Mammalian beta-defensins are small peptides of about 4.5-6 kDa in mass and are effectors of the innate immune response with potent anti-microbial activity. In this paper, we focused on the anti-influenza A activity of the recombinant mouse β-defensin 3 (rMBD-3) in vivo and in vitro.
METHODS:
The rMBD-3 peptide was added to MDCK cells at different stages of influenza A virus (IAV) A/PR/8/34 (H1N1) infection and its virus inhibitory properties were determined. Mice were infected with IAV and treated with rMBD-3 peptide from 12 hours post infection. The effect of rMBD-3 peptide was determined by measurement of pulmonary viral load, pathology, consolidation and mortality. In addition, the expression of IL-12, IFN-γ and TNF-α genes in mice with or without rMBD-3 treatment was determined by semi-quantitative RT-PCR.
RESULTS:
rMBD-3 was shown to protect MDCK cells against IAV infection and have a major role in inhibition of adsorption and uptake by cells of IAV. Following addition of 100 μg/ml rMBD-3 to MDCK cell medium approximately 80% of cells were protected from infection in vitro. rMBD-3 given by tail vein injection (10 mg/kg/day) was the most effective method to improve the survival rate of the mice. Treatment with rMBD-3 was found to up-regulate IFN-γ and IL-12 gene expression, but reduced expression of the TNF-α gene.
CONCLUSIONS:
These results demonstrate that rMBD-3 possesses anti-influenza virus activity both in vivo and in vitro that might be of therapeutic use. KEYWORDS: rMBD-3; influenza A virus; anti-virus activity; in vitro and in vivo.
PMID:
22345365
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22345365